Comparative Pharmacology
Head-to-head clinical analysis: PEPCID AC versus TRITEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID AC versus TRITEC.
PEPCID AC vs TRITEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
None Documented
None Documented
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min)
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Renal: 60% unchanged; fecal: 35% (mainly metabolites)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist/Antimicrobial Combination